Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab [8]

Acta Dermato-Venereologica

Volumn 85, Issue 6, 2005, Pages 534-535

  Al Shouli, Sadek ^a   Abouchala, Nabil ^a   Bogusz, Maciej J ^a   Tufail, Mohammad Al ^a   Thestrup Pedersen, Kristian ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; INFLIXIMAB; SILDENAFIL;

AGED; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; HOSPITAL ADMISSION; HUMAN; LETTER; MALE; MOUTH ULCER; PRIORITY JOURNAL; RASH; TOXIC EPIDERMAL NECROLYSIS;

AGED; ANTIBODIES, MONOCLONAL; COUMARINS; DERMATOLOGIC AGENTS; DRUGS, CHINESE HERBAL; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 30644473639     PISSN: 08003831     EISSN: 16512057     Source Type: Journal    
DOI: 10.1080/00015550510037062     Document Type: Letter

References (10)

1. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000; 18: 485-495.
2. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726-729.
3. Chiou WF, Huang YL, Chen CF. Vasorelaxing effect of coumarins from Cnidium monnieri on rabbit corpus cavernosum. Planta Med 2001; 67: 282-284.
4. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Sern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions. Lancet 1999; 353: 2190-2194.
5. Bogusz MJ, Al Tufail M, Hassan H. How natural are "Natural Herbal Remedies" - a Saudi perspective. Adv Drug React Toxicol Rev 2002; 21: 219-229.
6. Paquet P, Pierard GE. Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns. Int J Mol Med 1998; 1: 459-462.
7. Correia O, Delgado L, Barbosa IL, Campilho F, Fleming-Torrinha J. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002; 47: 58-62.
8. Wolkenstain P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589.
9. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146: 707-708.
10. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-36.